3rd Feb 2012 16:59
This announcement replaces the original announcement released on 1 July 2011 at 13.42 (RNS No: 6109J).
One of the Non-Executive Director's interests in the Ordinary shares of GlaxoSmithKline plc, indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 1 July 2011.
Save as disclosed above, all other details remain unchanged. The full amended text is shown below.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.
On 30 June 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £13.20 per Ordinary share and $42.43 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2011 to 30 June 2011:
Non Executive Director | Ordinary Shares | American Depository Shares (ADSs) |
Sir Christopher Gent | 2,556.818 | |
Prof. Sir Roy Anderson | 639.205 | |
Dr Stephanie Burns | 488.684 | |
Ms Stacey Cartwright | 355.114 | |
Mr Lawrence Culp | 977.369 | |
Sir Crispin Davis | 2,367.424 | |
Ms Judy Lewent | 174.530 | |
Sir Deryck Maughan | 977.369 | |
Mr James Murdoch | 1,420.455* | |
Dr Daniel Podolsky | 942.463 | |
Mr Tom de Swaan | 875.947 | |
Sir Robert Wilson | 639.205 |
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2011.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
Related Shares:
Glaxosmithkline